In the recent article in The Lancet by CJ. Black and AC. Ford which suggests a personalised approach to therapy in IBS ENTEROSGEL® is recommended as a first line treatment for IBS patients where diarrhoea and urgency are the main symptoms (Lancet Gastroenterol Hepatol 2024; 9: 1162–76). ENTEROSGEL® in recent years has become recognised by clinicians and doctors worldwide as an effective treatment for IBS. In the last 2 years, ENTEROSGEL® has been listed as an effective treatment in many articles outlining IBS management strategies and treatments.

Design After a 2-week screening phase, participants were randomised into an 8-week double-blind phase, followed by an 8-week open-label and follow-up phase. Participants recorded stool consistency, pain and global symptoms in e-diaries and questionnaires. Results 440 patients with IBS-D were randomised to the double-blind phase with 393 continuing to the open-label phase. Conclusion ENTEROSGEL® is safe and effective in IBS-D, providing an alternative to the limited current treatment options. ENTEROSGEL® significantly improves diarrhoea, pain, bloating and urgency in people with IBS diarrhoea and increases overall quality of life.

“The RELIEVE IBS-D study showed that 76% of patients that took ENTEROSGEL® reported adequate relief of their IBS symptoms. ENTEROSGEL® is an effective treatment option for patients with IBS-D.” – Professor Yan Yiannakou, Chief Investigator of RELIEVE-IBS-D study.

Methods This was a randomised controlled trial enrolling 105 subjects to receive the medical device ENTEROSGEL® up to six times daily for up to 8 days with standard care (oral rehydration solution), or standard care alone. Conclusions ENTEROSGEL® treatment was associated with a significant reduction in the duration of diarrhoea in adults with patient-reported acute diarrhoea, compared with standard care. These findings support the role of Enterosgel in acute diarrhoea especially in vulnerable groups where rapid resolution of symptoms is required. Reduction in symptom duration could translate to less healthcare costs and socioeconomic burden.

"The acute diarrhoea study showed that ENTEROSGEL® can reduce the duration of acute diarrhoea and relieve associated symptoms, and is one of the few safe treatment options currently available for children.” - Dr Preeti Pandya, Chief Investigator of Acute diarrhoea study in adults.

Methods Randomised controlled feasibility trial with two phases: phase 1 (0–4 hours and double-blind) and phase 2 (up to 5 days and open-label). 50 children aged 6–59 months with acute diarrhoea presenting with no or some dehydration to the emergency paediatric unit and outpatient clinic at Edward Francis Small Teaching Hospital, Banjul, The Gambia were randomised to either standard treatment (oral rehydration fluid and zinc) or standard treatment with polymethylsiloxane polyhydrate for up to 5 days.

Conclusions A clinical study in The Gambia , led by Professor Stephen Allen from Liverpool School of Tropical Medicine, showed that ENTEROSGEL® can be mixed directly into oral rehydration solution (ORS) and significantly reduces the duration of diarrhoea in children under 5 years old. The use of ENTEROSGEL® from the first day of diarrhoea can be life saving, as diarrhoea continues to be one of the leading causes of children’s death worldwide. ENTEROSGEL® is safe, easy to take and well tolerated by children.

ENTEROSGEL® is not new — it has a proven track record of over 40 years of clinical use worldwide. First developed in the early 1980s, it has been prescribed and recommended by doctors across Europe and beyond for a wide range of gastrointestinal conditions, from acute diarrhoea in children to chronic bowel disorders.

⚛︎ Millions of patients treated: ENTEROSGEL® has been trusted by families for three decades, with millions of tubes sold each year.
⚛︎ Backed by clinical research: More than 50 clinical trials and studies, including the UK-based Relieve-IBS-D trial, have confirmed its safety and effectiveness.
⚛︎ Recognised by healthcare systems: ENTEROSGEL® is listed in the NHS, making it available for the UK patients.
⚛︎ International reputation: It is registered as a medical device in the EU and is available in over 30 countries worldwide.

Unlike many new “gut health” supplements that appear on the market without strong data, ENTEROSGEL® has decades of real-world experience and peer-reviewed evidence behind it.

Why this matters:

⚛︎ Proven safety record — suitable from newborns to adults, including pregnancy and breastfeeding.
⚛︎ Non-allergenic and free from additives, making it ideal for sensitive patients with food intolerances or allergies.
⚛︎ Trusted by both doctors and patients for decades — not a fad, but a solid treatment option.
ENTEROSGEL® combines the reliability of long history with the strength of modern research, making it the first truly evidence-based, drug-free treatment option for IBS-D and other types of diarrhoea.

Ask your doctor about ENTEROSGEL®. Your doctor can find additional information on the Healthcare professional (HCPs) page on our website. ENTEROSGEL® is available in the independent pharmacies across the UK and in the selected stores of Boots. The dosage recommendations are included in every package of ENTEROSGEL® and are very simple to understand. You can choose the necessary dose depending on your symptoms and can increase or reduce it accordingly during treatment.